The 5-HT4R partial agonist usmarapride was demonstrated to produce elevation in cortical acetylcholine levels in rats and to increase levels of soluble amyloid precursor protein alpha, a potential mechanism to reverse toxic Aβ peptide pathology, which makes it a promising drug for alleviating the cognitive dysfunction in AD patients [29]. This evidence concerns the gene HTR4 and Alzheimer disease.